azza khalil retweetledi
📢 #ESMO25 concomitant paper: results from the largest and most diverse international, multicenter, retrospective study on leptomeningeal metastases from #NSCLC @Nicmmzh126
bit.ly/3J5dlqk
English
azza khalil
14.2K posts
azza khalil
@azza64
طبيبة مقيمة في الدنمارك. Views are my own . Clinical Oncologist Denmark
Katılım Temmuz 2008
880 Takip Edilen1.7K Takipçiler
azza khalil retweetledi
📢 #ESMO25 concomitant paper: results from the largest and most diverse international, multicenter, retrospective study on leptomeningeal metastases from #NSCLC @Nicmmzh126
bit.ly/3J5dlqk
English
Really meaningful work
Jarushka Naidoo@DrJNaidoo
#ESMO25 Thank you to the scientific committee for selecting our work for oral presentation: Patient-level analysis of Pneumonitis in Nivo-based regimens for solid tumors: - 11,777pts, 716 with pneumonitis (6.1%) - risk factors: age >65; NSCLC, smoking+, Ipi/nivo (p<0.005) 1/3
English
azza khalil retweetledi
Israeli orchestral conductor Ilan Volkov gave a heartfelt speech urging the world to stop Israel's slaughter in Gaza and help free the hostages in Gaza and in Israel.
English
azza khalil retweetledi
EGFR update
7 potential options:
•3rd gen TKI: osimertinib, lazertinib, aumolertinib
•Amivantamab
•Pemetrexed
•Carboplatin
•Ivonescimab
•Dato-DXd
OS data favor combos upfront—but real-world ≠ trial. In RWD, ~40% of newly diagnosed pts wouldn’t qualify for FLAURA2 #WCLC25
English
azza khalil retweetledi
English
azza khalil retweetledi
#WCLC25 Presidential
FLAURA2 OS in 1L EGFR+ NSCLC:
- mOS 47.5m v 37.6m (HR 0.77 p=0.02)
- duration of osi 30.5m on osi+chemo v 21.2m osi- combo delays acq resistance? - 72% got 2L chemo- does this add ~9m?
- all subgrps benefit (?BM, ?co-mtns)
Congrats @dplanchard @iaslc #LCSM
English
azza khalil retweetledi
Funny how two of the more interesting pieces of data at #ASCO25 have little to do with extraneous medications per se, but rather the body’s circadian rhythm and physiology:
1: Exercise after surgery
2: Checkpoint inhibitors in the morning
English
azza khalil retweetledi
Being part of a history-making drug that helps pts with #SCLC live longer and better is the biggest reward a thoracic oncologist could hope for.
Grateful being involved and to our pts
Just out in @NEJM
Presentation today by 1@only @charlesrudin
#ASCO25
English
azza khalil retweetledi
The most practice changing trial from #ASCO25 is now live on @NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival.
Perfect case example of a #cancergroundshot trial.
nejm.org/doi/full/10.10…
English
azza khalil retweetledi
#ELCC25 Lung Orals
1L MARIPOSA trial: Ami-Laz v Osi in EGFR+ NSCLC:
- OS benefit, 9% absolute benefit in 3-yr OS (HR 0.74, p<0.05)
- significant tox burden (IRRs, derm tox, VTE), mainly in first 4m, requiring prophylaxis
Throwing the field, on its head @myESMO @OncoAlert #LCSM
English
azza khalil retweetledi
📣Updated: ESMO Guidelines Slideset: Oncogene-Addicted Metastatic Non-small Cell Lung Cancer v1.2
👉 Find Clinical Practice Guideline recommendations in a condensed format, to include in your presentations.
#ESMOGuidelines
🔗ow.ly/sGmE50VnVwU
English
azza khalil retweetledi
azza khalil retweetledi
